Skip to Main Content

WASHINGTON — Medicare can’t seem to figure out how to pay for pricey CAR-T cancer therapies.

The latest glaring example of the struggle? A daylong advisory meeting Wednesday in Baltimore, ostensibly convened to discuss how patient-reported data should fit into the way Medicare pays for the therapies, devolved into a confusing debate about what the meeting was supposed to be about in the first place.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!